Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services.
It is undergoing a business transition and aims to build a CRDMO platform.[1]
- Market Cap ₹ 97.4 Cr.
- Current Price ₹ 27.6
- High / Low ₹ 70.0 / 25.6
- Stock P/E
- Book Value ₹ 13.5
- Dividend Yield 0.00 %
- ROCE -18.5 %
- ROE -26.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Debtor days have improved from 56.1 to 44.9 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.0%
- Company has a low return on equity of -19.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 4 | 0 | 15 | 19 | 28 | |
| 4 | 10 | 27 | 32 | 41 | |
| Operating Profit | 0 | -10 | -12 | -13 | -14 |
| OPM % | 3% | -82% | -66% | -49% | |
| 0 | 0 | 0 | 0 | 3 | |
| Interest | 0 | 0 | 2 | 2 | 3 |
| Depreciation | 0 | 0 | 2 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 | -16 |
| Tax % | 0% | -24% | -24% | -22% | -29% |
| 0 | -8 | -12 | -14 | -12 | |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.32 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -50% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 4% |
| 3 Years: | -3% |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -19% |
| Last Year: | -27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 | 12 |
| 0 | 0 | 9 | 39 | 23 | |
| 2 | 2 | 11 | 22 | 16 | |
| Total Liabilities | 11 | 25 | 91 | 120 | 87 |
| 0 | 0 | 63 | 77 | 54 | |
| CWIP | 0 | 2 | 7 | 5 | 6 |
| Investments | 0 | 3 | 0 | 0 | 0 |
| 11 | 19 | 21 | 39 | 27 | |
| Total Assets | 11 | 25 | 91 | 120 | 87 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -0 | -4 | -11 | -14 | -4 | |
| 0 | -5 | -75 | -12 | 23 | |
| 0 | 21 | 78 | 23 | -20 | |
| Net Cash Flow | 0 | 12 | -8 | -3 | -1 |
| Free Cash Flow | -0 | -6 | -33 | -26 | 11 |
| CFO/OP | -200% | 41% | 86% | 109% | 30% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | 45 | |
| Inventory Days | 91 | 0 | 112 | 359 | 9 |
| Days Payable | 236 | 159 | 480 | 59 | |
| Cash Conversion Cycle | -21 | 17 | -63 | -6 | |
| Working Capital Days | -18 | -69 | -160 | -172 | |
| ROCE % | -64% | -26% | -17% | -19% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Work-in-Progress (Standalone) INR Lakhs ・Standalone data |
|
|||||||||||
| Electricity Consumption Units (KWH) ・Standalone data |
||||||||||||
| Number of Permanent Employees Number ・Standalone data |
||||||||||||
| Land Assets (Manufacturing/R&D) Acres ・Standalone data |
||||||||||||
| GLP Certified Research Facilities Number |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Newspaper publication of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026
-
Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2026
29 May - Board approved FY26 audited standalone and consolidated results and a Rs.75 lakh corporate guarantee for Adita Bio Sys.
-
Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended March 31 2026
29 May - Board approved March 31, 2026 audited results and Rs.75 lakh corporate guarantee for subsidiary Adita Bio Sys.
-
Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2026.
22 May - Board meeting on May 29, 2026 to approve audited FY26 standalone and consolidated results.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
8 May - FY26 Annual Secretarial Compliance Report filed; no non-compliances or regulatory actions observed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview[1]
The company is engaged in research, development, and manufacturing services.
It is pursuing organic and inorganic growth opportunities and is in the process of a business transition, including strengthening its leadership team. It is working towards establishing a Contract Research, Development, and Manufacturing Organization (CRDMO) to offer integrated services across pharma, biopharma, agrochemicals, medical devices, and specialty chemicals for domestic and international markets.